TOKYO, Apr 27 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) reported impairment losses totaling ¥16.40 billion related to its gene therapy drug AT132 and a special loss of ¥74.80 billion due to a decline in the value of shares held in Ogeda B.V.'s subsidiary in its individual quarter-end results for the fiscal year ending March 2026.
The impairment loss was recorded as part of other expenses due to a reassessment of asset value following the strategic interruption of the AT132 program and a shift towards next-generation gene therapy ASP2,957. This adjustment reflects the company's ongoing efforts to realign resources and focus on more promising therapeutic avenues. The special loss, however, will be eliminated in the consolidated financial statements and thus will not impact the overall linked earnings.
In addition, Astellas continues to develop innovative treatments across various fields such as oncology, ophthalmology, urology, immunology, and women’s health. The company aims to transform scientific advancements into patient value through its research and development programs targeting unmet medical needs. Investors should note that forward-looking statements within this press release are based on current estimates and assumptions and involve risks and uncertainties that could cause actual outcomes to differ materially.
Factors influencing future performance include changes in the pharmaceutical industry environment, regulatory reforms, exchange rate fluctuations, delays in product launches, competitive pressures, and intellectual property infringements.
🟢 Confidence: High AI-translated content.